Therapeutic formulations favoring skeletal muscle health—especially in case of diabetes mellitus—is necessary because, in the insulin-resistant mechanism, there is impairment in insulin signaling pathways causing a lethal effect on glucose levels, resulting in abnormal glucose metabolism, insulin resistance, and low skeletal muscle mass [9,10]. This evidence concerns the gene INS and diabetes mellitus.